Selpercatinib Receives Traditional FDA Approval for RET Fusion–Positive Solid Tumors

The FDA has granted traditional approval to selpercatinib for advanced or metastatic RET fusion-positive solid tumors in patients aged 2 and older who have received prior treatment. This approval provides a new treatment option for a specific subset of cancers.